Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of BioCon Expo 2024. The discussion will revolve around the differentiated development strategy of antibody drugs, with a presentation on the topic of 'Research Progress on Inhalable Nanobody Drugs Therapy for Asthma.' Everyone is welcome to join the online discussion.

Main content of the speech:

1. Clinical needs for asthma treatment and the market landscape of antibody drugs;

2. Introduction to Luoqi Biotech's differentiated platform for inhaled nanobodies;

3. Progress in the clinical development of inhaled nanobodies against IL-4Rα and TSLP;

About BioCon Expo 2024

As an important exhibition and exchange platform in the domestic biopharmaceutical industry, the 11th International Biopharmaceutical Conference and Exhibition, BioCon China Expo 2024, will be held in Beijing from April 10 to 11, 2024. With the annual theme of 'Adapt to Change, Pursue Long-Term Vision with Sincerity,' the high-level forum will take the pulse of new trends in the development of the biopharmaceutical industry, promote new cooperation in the connection of the upstream and downstream industry chains, and set new benchmarks for investment and financing. The thematic discussions will comprehensively cover key new technologies from the entire lifecycle of the biopharmaceutical industry, from R&D innovation to commercial production, in hot fields such as nucleic acid drugs, gene drugs, cell therapy, antibody drugs, chemical drugs, and synthetic biology, promoting high-quality development of the industry!

About Novamab

Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise dedicated to the research and industrialization of nanobody drugs. The company was established in October 2017 and is located in the Shanghai International Medical Park. It has established a complete research and development, CMC, and pilot production platform and system, and is currently the only company in China with the capability for full-process development of nanobodies. Novamab has built a 500 L Pichia pastoris nanobody GMP pilot production workshop, filling an industry gap in this field with high scarcity and competitiveness. As of January 2024, more than 80 domestic and foreign invention patents have been applied for, and 28 have been authorized. Novamab has developed dozens of nanobody drugs, with a pipeline covering fields such as respiratory system, autoimmune, ophthalmology, and oncology. Currently, it has obtained four clinical approvals. The LQ036 and LQ043H products under development by Novamab have overturned the existing treatment methods for respiratory diseases, both of which are the world's first inhaled nanobody drugs of their respective target. LQ036 for asthma has completed clinical Phase I trials in China and Australia (completed), demonstrating excellent safety and tolerability in human trials and has now entered Phase II clinical research. The clinical trial for LQ036 for COPD indication was approved by the CDE in September 2023. The Phase Ia clinical study for LQ043H for asthma indication in China has been completed, with good safety, and is about to enter Phase Ib/II clinical research. LQ043H complements the patient population of LQ036, and the two projects cover the entire population of patients with moderate to severe asthma.